A novel three-dimensional large-pore mesoporous carbon matrix as a potential nanovehicle for the fast release of the poorly water-soluble drug, celecoxib

Pharmaceutical Research

Volumn 31, Issue 4, 2014, Pages 1059-1070

  Zhang, Yanzhuo ^a   Wang, Hong ^b   Li, Chuanjun ^c   Sun, Baoxiang ^c   Wang, Yu ^a   Wang, Siling ^b   Gao, Cunqiang ^c  

^a XUZHOU MEDICAL UNIVERSITY   (China)

^b SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^c Jiangsu Hengrui Medicine Co Ltd   (China)

Author keywords

carbon matrix; crystallinity; cytotoxicity; dissolution; drug absorption

Indexed keywords

CARBON; CELECOXIB; NANOPARTICLE; DRUG CARRIER; PYRAZOLE DERIVATIVE; SULFONAMIDE; WATER;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BIOAVAILABILITY; CELL VIABILITY; CONTROLLED STUDY; DRUG SOLUBILITY; EVAPORATION; IMMERSION; MALE; NONHUMAN; PARTICLE SIZE; POROSITY; PRIORITY JOURNAL; RAT; ANIMAL; CACO 2 CELL LINE; CHEMISTRY; DRUG EFFECTS; HUMAN; METABOLISM; SOLUBILITY; SPRAGUE DAWLEY RAT;

ANIMALS; CACO-2 CELLS; CARBON; DRUG CARRIERS; HUMANS; MALE; NANOPARTICLES; POROSITY; PYRAZOLES; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; SULFONAMIDES; WATER;

EID: 84897042307     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-013-1227-9     Document Type: Article

References (45)

1. Hörter D, Dressman JB. Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Adv Drug Deliv Rev. 2001;46(1-3):75-87.
2. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development setting. Adv Drug Deliv Rev. 1997;23(1-3):3-25.
3. Kawabata Y, Wada K, Nakatani M, Yamada S, Onoue S. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications. Int J Pharm. 2001;420(1):1-10.
4. Lukyanov AN, Torchilin VP. Micelles from lipid derivatives of water-soluble polymers as delivery systems for poorly soluble drugs. Adv Drug Deliv Rev. 2004;56(9):1273-89.
5. Huanga LF, Tong WQT. Impact of solid state properties on developability assessment of drug candidates. Adv Drug Del Rev. 2004;56(3):321-34.
6. Kipp JE. The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs. Int J Pharm. 2004;284(1-2):109-22.
7. Chen H, Khemtong C, Yang X, Chang X, Gao J. Nanonization strategies for poorly water-soluble drugs. Drug Discov Today. 2011;16(7-8):354-60.
8. Vasconcelos T, Sarmento B, Costa P. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov Today. 2007;12(23-24):1068-75.
9. LaVan DA, McGuire T, Langer R. Small-scale systems for in vivo drug delivery. Nat Biotechnol. 2003;21:1184-91.
10. Merisko-Liversidge E, Liversidge GG. Nanosizing for oral and parenteral drug delivery: a perspective on formulating poorly-water soluble compounds using wet media milling technology. Adv Drug Deliv Rev. 2011;63(6):427-40.
11. Eerdenbrugh BV, Mooter GV, Augustijns P. Top-down production of drug nanocrystals: nanosuspension stabilization, miniaturization and transformation into solid products. Int J Pharm. 2008;364(1):64-75.
12. Ghosh I, Bose S, Vippagunta R, Harmon F. Nanosuspension for improving the bioavailability of a poorly soluble drug and screening of stabilizing agents to inhibit crystal growth. Int J Pharm. 2011;409(1-2):260-8.
13. Constantinides PP, Chaubal MV, Shorr R. Advances in lipid nanodispersions for parenteral drug delivery and targeting. Adv Drug Del Rev. 2008;60(6):757-67.
14. Kesisoglou F, Panmai S, Wu Y. Nanosizing-Oral formulation development and biopharmaceutical evaluation. Adv Drug Del Rev. 2007;59(7):631-44.
15. Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm. 2008;5(4):505-15.
16. Barbé C, Bartlett J, Kong L, Finnie K, Lin HQ, Larkin M, et al. Silica particles: a novel drug-delivery system. Adv Mater. 2004;16(21):1949-66.
17. Jaganathan H, Godin B. Biocompatibility assessment of Si-based nano- and micro-particles. Adv Drug Deliv Rev. 2012;64(15):1800-19.
18. Trewyn BG, Slowing II, Giri S, Chen HT, Lin VSY. Synthesis and functionalization of a mesoporous silica nanoparticle based on the sol-gel process and applications in controlled release. Acc Chem Res. 2007;40(9):846-53.
19. Yang F, Gai S, Lin J. Functionalized mesoporous silica materials for controlled drug delivery. Chem Soc Rev. 2012;41(9):3679-98.
20. Zhang Y, Wang J, Bai X, Jiang T, Zhang Q, Wang S. Mesoporous silica nanoparticles for increasing the oral bioavailability and permeation of poorly water soluble drugs. Mol Pharm. 2012;9(3):505-13.
21. Thomas MJK, Slipper I, Walunj A, Jain A, Favretto ME, Kallinteri P, et al. Inclusion of poorly soluble drugs in highly ordered mesoporous silica nanoparticles. Int J Pharm. 2009;387(1-2):272-7.
22. Zhang Y, Zhi Z, Jiang T, Zhang J, Wang Z, Wang S. Spherical mesoporous silica nanoparticles for loading and release of the poorly water-soluble drug telmisartan. J Control Release. 2010;145(3):257-63.
23. Li Z, Barnes JC, Bosoy A, Stoddart JF, Zink JI. Mesoporous silica nanoparticles in biomedical applications. Chem Soc Rev. 2012;41(7):2590-605.
24. Wani A, Muthuswamy E, Savithra GHL, Mao G, Brock S, Oupický D. Surface functionalization of mesoporous silica nanoparticles controls loading and release behavior of mitoxantrone. Pharm Res. 2012;29(9):2407-18.
25. Vignolini S, Yufa NA, Cunha PS, Guldin S, Rushkin I, Stefik M, et al. A 3D optical metamaterial made by self-assembly. Adv Mater. 2012;24(10):23-7.
26. Ji X, Lee KT, Nazar LF. A highly ordered nanostructured carbon-sulphur cathode for lithium-sulphur batteries. Nat Mater. 2009;8:500-6.
27. Liang C, Li Z, Dai S. Mesoporous carbon materials: synthesis and modification. Angew Chem. 2008;47(20):3696-717.
28. Wang X, Liu P, Tian Y. Ordered mesoporous carbons for ibuprofen drug loading and release behavior. Micropor Mesopor Mater. 2011;142(1):366-85.
29. Zhao P, Wang L, Sun C, Jiang T, Zhang J, Zhang Q, et al. Uniform mesoporous carbon as a carrier for poorly water soluble drug and its cytotoxicity study. Eur J Pharm Biopharm. 2012;80(3):535-43.
30. Heikkilä T, Salonen J, Tuura J, Hamdy MS, Mul G, Kumar N, et al. Mesoporous silica material TUD-1 as a drug delivery system. Int J Pharm. 2007;331(1):133-8.
31. Rosenholm JM, Lindén M. Towards establishing structure-activity relationships for mesoporous silica. J Control Release. 2008;128(2):157-64.
32. Wang S. Ordered mesoporous materials for drug delivery. Micropor Mesopor Mater. 2009;117(1-2):1-9.
33. Vallet-Regí M, Balas F, Arcos D. Mesoporous materials for drug delivery. Angew Chem Int Edit. 2007;46(40):7548-58.
34. Tatsuda N, Yano K. Pore size control of monodispersed starburst carbon spheres. Carbon. 2013;51:27-35.
35. 1 alloy nanoparticles in large pore size mesocellular carbon foam for improved methanol-tolerant oxygen reduction reaction. Carbon. 2011;49(4):1108-17.
36. 4 nanoparticles using ordered mesoporous carbons as a template and their application for fischer-tropsch synthesis. J Phys Chem C. 2013;117(4):1773-9.
37. Dolenc A, Kristl J, Baumgartner S, Planinšek O. Advantages of celecoxib nanosuspension formulation and transformation into tablets. Int J Pharm. 2009;376(1-2):204-12.
38. Paulson SK, Vaughn MB, Jessen SM, Lawal Y, Gresk CJ, Yan B, et al. Pharmacokinetics of celecoxib after oral administration in dogs and humans: effect of food and site of absorption. J Pharmacol Exp Ther. 2001;297(2):638-45.
39. Zhang Y, Zhang J, Jiang T, Wang S. Inclusion of the poorly water-soluble drug simvastatin in mesocellular foam nanoparticles: Drug loading and release properties. Int J Pharm. 2011;410(1-2):118-24.
40. Yan X, He P, Xia Y. Preparation of mesocellular carbon foam and its application for lithium/oxygen battery. Electrochem Commun. 2009;11(6):1127-30.
41. Yu L. Amorphous pharmaceutical solids: preparation, characterization and stabilization. Adv Drug Deliv Rev. 2001;48(1):27-42.
42. Skinner LM, Sambles JR. The Kelvin equation - a review. J Aerosol Sci. 1972;3(3):199-210.
43. Noyes AS, Whitney WR. The rate of solution of solid substances in their own solutions. J Am Chem Soc. 1897;19(12):930-4.
44. Horcajada P, Rámila A, Pérez-Pariente J, Vallet-Regi M. Influence of pore size of MCM-41 matrices on drug delivery rate. Micropor Mesopor Mater. 2004;68(1-3):105-9.
45. Cauda V, Muhlstein L, Onida B, Bein T. Tuning drug uptake and release rates through different morphologies and pore diameters of confined mesoporous silica. Micropor Mesopor Mater. 2009;118(1-3):435-43.